Procept Biorobotics Corp Net Income
| PRCT Stock | USD 28.96 0.16 0.55% |
As of the 31st of January, Procept Biorobotics holds the Risk Adjusted Performance of (0.03), variance of 13.78, and Coefficient Of Variation of (1,759). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Procept Biorobotics, as well as the relationship between them.
Procept Biorobotics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 4.7076 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -82.3 M | -86.4 M | |
| Net Loss | -78.4 M | -82.4 M | |
| Net Loss | -82.3 M | -86.4 M | |
| Net Loss | (2.02) | (2.12) |
Procept | Net Income | Build AI portfolio with Procept Stock |
The evolution of Net Income for Procept Biorobotics Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Procept Biorobotics compares to historical norms and industry peers.
Latest Procept Biorobotics' Net Income Growth Pattern
Below is the plot of the Net Income of Procept Biorobotics Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Procept Biorobotics Corp financial statement analysis. It represents the amount of money remaining after all of Procept Biorobotics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Procept Biorobotics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Procept Biorobotics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (91.41 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Procept Net Income Regression Statistics
| Arithmetic Mean | (57,984,881) | |
| Coefficient Of Variation | (39.16) | |
| Mean Deviation | 19,419,376 | |
| Median | (41,975,000) | |
| Standard Deviation | 22,709,570 | |
| Sample Variance | 515.7T | |
| Range | 63.9M | |
| R-Value | (0.82) | |
| Mean Square Error | 177.5T | |
| R-Squared | 0.68 | |
| Significance | 0.00005 | |
| Slope | (3,701,067) | |
| Total Sum of Squares | 8251.6T |
Procept Net Income History
Other Fundumenentals of Procept Biorobotics Corp
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Procept Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Procept Biorobotics is extremely important. It helps to project a fair market value of Procept Stock properly, considering its historical fundamentals such as Net Income. Since Procept Biorobotics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Procept Biorobotics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Procept Biorobotics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Equipment & Supplies market expansion? Will Procept introduce new products? Factors like these will boost the valuation of Procept Biorobotics. Anticipated expansion of Procept directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Procept Biorobotics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share | Quarterly Revenue Growth 0.428 | Return On Assets | Return On Equity |
Understanding Procept Biorobotics Corp requires distinguishing between market price and book value, where the latter reflects Procept's accounting equity. The concept of intrinsic value—what Procept Biorobotics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Procept Biorobotics' price substantially above or below its fundamental value.
It's important to distinguish between Procept Biorobotics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Procept Biorobotics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Procept Biorobotics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Procept Biorobotics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Procept Biorobotics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Procept Biorobotics.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Procept Biorobotics on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Procept Biorobotics Corp or generate 0.0% return on investment in Procept Biorobotics over 90 days. Procept Biorobotics is related to or competes with Twist Bioscience, Guardian Pharmacy, Mesoblast, Qilian International, Quidel, Edgewise Therapeutics, and Clover Health. PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology More
Procept Biorobotics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Procept Biorobotics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Procept Biorobotics Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 17.63 | |||
| Value At Risk | (5.10) | |||
| Potential Upside | 7.06 |
Procept Biorobotics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Procept Biorobotics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Procept Biorobotics' standard deviation. In reality, there are many statistical measures that can use Procept Biorobotics historical prices to predict the future Procept Biorobotics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.12) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Procept Biorobotics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Procept Biorobotics January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 2.75 | |||
| Coefficient Of Variation | (1,759) | |||
| Standard Deviation | 3.71 | |||
| Variance | 13.78 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 17.63 | |||
| Value At Risk | (5.10) | |||
| Potential Upside | 7.06 | |||
| Skewness | 0.7999 | |||
| Kurtosis | 1.64 |
Procept Biorobotics Corp Backtested Returns
Procept Biorobotics Corp maintains Sharpe Ratio (i.e., Efficiency) of -0.0581, which implies the firm had a -0.0581 % return per unit of risk over the last 3 months. Procept Biorobotics Corp exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Procept Biorobotics' Variance of 13.78, risk adjusted performance of (0.03), and Coefficient Of Variation of (1,759) to confirm the risk estimate we provide. The company holds a Beta of 1.84, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Procept Biorobotics will likely underperform. At this point, Procept Biorobotics Corp has a negative expected return of -0.22%. Please make sure to check Procept Biorobotics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Procept Biorobotics Corp performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.58 |
Good reverse predictability
Procept Biorobotics Corp has good reverse predictability. Overlapping area represents the amount of predictability between Procept Biorobotics time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Procept Biorobotics Corp price movement. The serial correlation of -0.58 indicates that roughly 58.0% of current Procept Biorobotics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.58 | |
| Spearman Rank Test | -0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 2.6 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Procept Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Procept Biorobotics Corp reported net income of (91.41 Million). This is 126.79% lower than that of the Health Care Equipment & Supplies sector and 138.39% lower than that of the Health Care industry. The net income for all United States stocks is 116.01% higher than that of the company.
Procept Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Procept Biorobotics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Procept Biorobotics could also be used in its relative valuation, which is a method of valuing Procept Biorobotics by comparing valuation metrics of similar companies.Procept Biorobotics is currently under evaluation in net income category among its peers.
Procept Biorobotics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Procept Biorobotics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Procept Biorobotics' managers, analysts, and investors.Environmental | Governance | Social |
Procept Biorobotics Institutional Holders
Institutional Holdings refers to the ownership stake in Procept Biorobotics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Procept Biorobotics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Procept Biorobotics' value.| Shares | Artisan Partners Limited Partnership | 2025-06-30 | 986.3 K | Baillie Gifford & Co Limited. | 2025-06-30 | 876.4 K | Axa Sa | 2025-06-30 | 850.5 K | Bnp Paribas Investment Partners Sa | 2025-06-30 | 784.2 K | Jpmorgan Chase & Co | 2025-06-30 | 765 K | Mackenzie Investments | 2025-06-30 | 708.7 K | Mirae Asset Global Etfs Holdings Ltd. | 2025-06-30 | 687.7 K | Bank Of America Corp | 2025-06-30 | 625.7 K | Wellington Management Company Llp | 2025-06-30 | 615.2 K | Fmr Inc | 2025-06-30 | 7.8 M | Vanguard Group Inc | 2025-06-30 | 5.2 M |
Procept Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 1.41 B | ||||
| Shares Outstanding | 55.88 M | ||||
| Shares Owned By Insiders | 4.41 % | ||||
| Shares Owned By Institutions | 95.59 % | ||||
| Number Of Shares Shorted | 6.58 M | ||||
| Price To Book | 4.28 X | ||||
| Price To Sales | 5.43 X | ||||
| Revenue | 224.5 M | ||||
| Gross Profit | 193.58 M | ||||
| EBITDA | (82 M) | ||||
| Net Income | (91.41 M) | ||||
| Cash And Equivalents | 269.81 M | ||||
| Cash Per Share | 6.05 X | ||||
| Total Debt | 80.25 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 16.01 X | ||||
| Book Value Per Share | 6.81 X | ||||
| Cash Flow From Operations | (99.21 M) | ||||
| Short Ratio | 6.08 X | ||||
| Earnings Per Share | (1.53) X | ||||
| Price To Earnings To Growth | (0.47) X | ||||
| Target Price | 50.73 | ||||
| Number Of Employees | 756 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 1.63 B | ||||
| Total Asset | 534.02 M | ||||
| Retained Earnings | (545.99 M) | ||||
| Working Capital | 428.71 M | ||||
| Net Asset | 534.02 M |
About Procept Biorobotics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Procept Biorobotics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Procept Biorobotics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Procept Biorobotics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.